Immunotherapy drugs approved for the treatment of multiple tumor types include anti-PD-1 (pembrolizumab, nivolumab and cemiplimab), anti-PD-L1 (atezolizumab, durvalumab and avelumab), and the cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) (ipilimumab and tremelimumab) (52). This evidence concerns the gene PDCD1 and neoplasm.